The independent clinical correlates and prognostic impact of QRS prolongation in heart failure (HF) with reduced and preserved ejection fraction (EF) are poorly understood. The rationale for cardiac resynchronization therapy (CRT) in preserved EF is unknown. The aim was to determine the prevalence of, correlates with, and prognostic impact of QRS prolongation in HF with reduced and preserved EF.
Introduction
Heart failure (HF) affects 2-3% of the adult population and is associated with 50% mortality at 4 years, varying depending on severity. 1 Heart failure with reduced ejection fraction (HFrEF), sometimes termed systolic HF, is well characterized and drug and device therapy improve prognosis. 1 Heart failure with preserved ejection fraction (HFpEF), sometimes termed diastolic HF, is perhaps equally common and lethal as HFrEF, 2, 3 but is poorly characterized and there is no evidence-based therapy.
In the general population, QRS prolongation and/or left bundle branch block (LBBB) is present in ,1% at middle age, increasing to 5 -17% over age 80, occurring more commonly in male gender, HF, coronary artery disease, hypertension, and left ventricular hypertrophy, and associated with adverse outcomes. 4 -7 In HFrEF, QRS prolongation and/or LBBB is present in 24-47% and thought to be associated with increased mortality, 8 -11 although others report no increased risk. 12, 13 In HFpEF, non-specific QRS prolongation has not been studied but LBBB appears present in 8 -40%, with a conflicting impact on outcome. 9, 14 These studies were relatively small, with limited covariate adjustment and potential confounding as well as conflicting results. Whether QRS prolongation is merely a risk marker of HF and its severity or actually a risk factor for HF progression and mortality is unknown. Reduced mortality with cardiac resynchronization therapy (CRT) in HFrEF 1 suggests a risk factor effect of QRS prolongation that is responsive to intervention, but the independent clinical correlates and prognostic implications of QRS prolongation are still poorly understood. Whether CRT might be of benefit in HFpEF is unknown. We hypothesized that QRS prolongation is an independent risk factor for mortality in both HFrEF and HFpEF, and that therefore CRT may be of benefit also in HFpEF. Therefore, we performed a comprehensive prospective assessment of the prevalence, correlates, and prognostic role of QRS prolongation in HFrEF and HFpEF.
Methods

Study protocol
The Swedish Heart Failure Registry (RiksSvikt) has been previously described. 15, 16 The inclusion criterion is clinician-judged HF. Eighty variables are recorded at discharge from hospital or after clinic visit and entered into an electronic database managed by the Uppsala Clinical Research Center (Uppsala, Sweden). The database is run against the Swedish death registry monthly. The protocol, registration form, and annual report are available at http://www.rikssvikt.se. Establishment of the registry and registration and analysis of data was approved by a multisite Ethics Committee. The registry and this study conform to the Declaration of Helsinki. Individual patient consent is not required or obtained, but patients are informed of being entered into national registries and are allowed to opt out. Between 11 May 2000 and 12 March 2011, there were 57 879 registrations from 63 of 77 hospitals and 76 of 1011 primary care outpatient clinics in Sweden, representing 37 974 unique patients. QRS width is not recorded in patients with a pacemaker, CRT, and/or implantable cardioverter defibrillator (n ¼ 5150), and of the remainder, 6933 were excluded because QRS width was missing, 9 because of missing followup, and 711 because of inconsistency between entered LBBB and QRS width (LBBB present and QRS ,120 ms), leaving 25 171 patients.
Statistical analysis
Data handling and descriptive statistics were performed in SAS version 9.2 (SAS Institute, Inc., Cary, NC, USA) and all other analyses in R version 2.9.2 (R Foundation for Statistical Computing, Vienna, Austria). For all analyses, the level of significance was set to 5% and all reported P-values are two-sided.
QRS width was categorized by ≥120 vs. ,120 ms and analysed as categorical unless otherwise stated. QRS width contains more physiological and statistical information as a continuous variable, but the dichotomization at the 120 ms cut-off is clinically more useful. Forty additional clinically relevant baseline variables (including LBBB) were selected for analysis (depicted in Table 1 ). To avoid bias and confounding due to baseline variables missing at random, multiple imputation (n ¼ 10) was performed for all variables with any missing data, using predictive mean matching with QRS width as a continuous variable and variables in Table 1 (according to the aregImpute function in R: http://CRAN.R-project.org/package=Hmisc). The outcome, survival, was included as the Nelson-Aalen estimator in the imputation model, although not imputed itself since it contained no missing values. Descriptive statistics report raw data and specifies % missing for each variable, but all subsequent analyses were performed on imputed data with imputation corrections to the resulting standard errors. The same imputed values were used for all regression and subgroup analyses.
Association of baseline variables with QRS width
Several univariable and multivariable logistic regressions were performed with QRS width as the outcome ( Table 1) . The le Cessie-van Houwlingen goodness-of-fit test was performed for the multivariable model and the resulting P-value was low, which could indicate problems with the overall fit of the model; however, this could also be an effect of the large number of observations and since no discrepancies between the predicted and observed values were detected when validating the model using bootstrapping (200 replications; http://CRAN.R-project.org/package=Design), the latter was deemed probable. The c-statistic was 0.70, considered acceptable discrimination. 17 No extreme outliers were detected (Cook's distance ,1 for all observations) and the largest variance inflation factor value was 3, so multicollinearity was deemed low. Linearity for the continuous variables was assessed using smoothed partial residuals plots and as a result N-terminal pro-brain natriuretic peptide (NT-proBNP) was logtransformed, whereas pulse pressure, heart rate, and creatinine clearance were categorized according to clinically relevant cut-offs ( Table 1) .
Survival according to QRS width
Survival for QRS width was charted with the Kaplan-Meier method. Several univariable and multivariable Cox regressions, using the Efron method for tie handling, were performed separately for QRS width as a categorical and continuous variable ( Table 2) . In order to evaluate the individual effect of the respective variables on the association between QRS width and mortality, bivariable models were also estimated for QRS width. The proportional hazards assumption was investigated for the scaled Schoenfeld residuals from the multivariable models and the dfbetas [a measure of how much the hazard ratio (HR) changes due to the deletion of a single observation] from the models were inspected to detect outliers, 18 but no problems were detected.
The assumption of linearity for the continuous variables was investigated using smoothed Martingale residuals plots, and variables deemed not to have a linear relationship with the outcome, creatinine clearance and NT-proBNP, were modelled using restricted cubic splines (enabling non-linear relationships between these variables and the outcome to be modelled) with 4 degrees of freedom.
18
Patient inclusion occurred largely before NT-proBNP was widely used, and 74.8% of patients had NT-proBNP missing. Therefore, a consistency analysis was performed excluding NT-proBNP from the multiple imputation and Cox regressions.
Interactions between QRS width and all covariates were estimated within the multivariable Cox regressions. Continuous variables were analysed as such when assessing interactions but dichotomized at clinically relevant cut-offs when displayed in a forest plot (Figure 3 ). Four pre-specified and clinically relevant subgroup Cox analyses were performed, by EF ,30, 30 -39, 40-49, and ≥50%.
Results
Baseline characteristics and associations with QRS width
Baseline characteristics are shown in Data are mean (standard deviation) or n (%), with the exception of follow-up, which lists median (inter-quartile range, range).
Boldface indicates values statistically significant in multivariable analysis. P-values are nominal, without correction for multiplicity. With Bonferroni adjustment (correcting for 37 tests), the following variables were no longer statistically significantly associated with QRS prolongation: creatinine clearance, haemoglobin, aldosterone antagonist, diuretic. OR, odds ratio; when comparing two or more groups, the reference is the group with no OR listed; CI, confidence interval; NT-proBNP, N-terminal brain natriuretic peptide; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft. a Not included in logistic regressions (left bundle branch block not present in narrow QRS; death and follow-up time, planned follow-up specialty and planned follow-up in heart failure nurse clinic considered future events which may affect prognosis but should not affect present association with QRS width). Used to derive mean arterial pressure and pulse pressure. Not included in imputations or regressions, but included here for completeness. Presented as continuous but because of non-linear association with QRS width, categorized or log-transformed for logistic regressions, as appropriate. *P , 0.05. **P , 0.01. ***P , 0.001. women), 31% had a QRS width of ≥120 ms. QRS width ≥120 ms was present in 46, 33, 25, and 18% in the EF groups ,30, 30 -39, 40 -49, and ≥50%, respectively (P , 0.001). Numerous characteristics were independently associated with QRS ≥120 ms ( Outcome One-year survival was 77% in QRS ≥120 vs. 82% in QRS ,120 ms, and 5-year survival was 42 and 51%, respectively (log-rank P , 0.001) (Figure 2 ). Figure 3 . There were several statistically significant interactions between QRS width and covariates; however, in none of the resulting subgroups did the entire 95% CI of the HR fall below 1.00. The interactions between QRS width and NYHA class and QRS width and EF were not significant, but there were signals towards greater risk associated with QRS prolongation with lower EF and with better NYHA class.
In a sensitivity analysis without NT-proBNP, the multivariable HR for QRS ≥120 was 1.14 (95% CI 1.08-1.21, P , 0.001).
Of the 31% with QRS ≥120, 56% had LBBB. The multivariable HR for LBBB vs. QRS ,120 ms was 1.11 (95% CI 1.05-1.18, P , 0.001) and for non-specific intraventricular conduction delay (QRS ≥120 without LBBB) vs. QRS ,120 ms, the multivariable HR was also 1.11 (95% 1.04-1.18, P , 0.001) ( Table 2) . Table 2 depicts HRs by QRS width for the four EF subgroups. QRS prolongation was independently associated with increased mortality as a categorical and continuous variable for all subgroups with a few exceptions ( Table 2) . QRS prolongation was associated with higher excess hazard in lower EF subgroups. However, as mentioned, there was no interaction between EF and QRS width as a continuous (P ¼ 0.610) or categorical (P ¼ 0.256, Figure 3 ) variable.
Subgroup outcomes
Discussion
QRS prolongation on the electrocardiogram represents intraventricular conduction delay, and since it was first noted to be associated with increased mortality in HF in the 1960s, 19 it has been thought to be merely a risk marker of underlying structural heart disease. However, with the success of CRT in the 2000s, 1 there is renewed interest for the clinical correlates of QRS prolongation and its role as a direct risk factor for HF progression and death, amenable to intervention. We show that QRS prolongation ≥120 ms was present in 31% of patients with HF in the Swedish Heart Failure Registry. It was more common with reduced than with preserved EF, but once it occurred, it was an independent risk factor for mortality regardless of EF, suggesting CRT may be beneficial also in HFpEF. There was a signal towards greater risk with better NYHA class, suggesting the potential benefit of CRT could actually be greater in milder HF. Correlates with and risk factors for QRS prolongation QRS prolongation occurs in the general population, increasing sharply with age. 4 -6 Normal ageing may be associated with fibrosis in the conduction system. 20 QRS duration is also related to cardiac size and thus gender, and is associated with hypertension, left ventricular hypertrophy and fibrosis, and ischaemic heart disease, all of which may be subclinical. 4 -6 In our study, each decade of life was associated with a 35% increased odds of QRS ≥120 ms, independently of other covariates known to be associated with QRS prolongation and severity of HF, suggesting that ageing itself is important not only in the general population but also in HF. QRS prolongation is mainly associated with structural heart disease, such as in HF. In our study, QRS ≥120 ms was present in 31% overall and in 39% of patients with reduced EF (,40%), 25% in patients with mildly reduced EF (40-49%) and 18% with normal EF (≥50%). These prevalences were slightly higher than previous reports of QRS prolongation/LBBB in HFrEF 8 -12 and slightly lower than the few previous reports of LBBB in HFpEF, 9,14 and they confirm the important proportional and Association class, and gender. As ejection fraction increases, the proportion of women increases, New York Heart Association class improves, and the proportion with QRS ≥120 ms decreases. Data are not imputed.
independent association of LV dilatation and systolic dysfunction with QRS prolongation. 21 The ORs of QRS prolongation associated with EF was similar in univariable and multivariable analyses, suggesting EF is not only a risk marker but also a risk factor for QRS prolongation. However, the 18% prevalence of QRS prolongation in the EF ≥50% group was still higher than in the general population, 4 -6 suggesting that the pathophysiology of HFpEF (cellular and ventricular hypertrophy, fibrosis of the conduction system and myocardium, ischaemia, and diastolic dysfunction 22 ) contributes to QRS prolongation despite normal EF.
Dilated cardiomyopathy was strongly associated with QRS prolongation, independent of EF, and the ORs were similar in multivariable and univariable analyses, again suggesting a risk factor role. In contrast, ischaemic aetiology was not associated with QRS width, suggesting that ischaemic aetiology and focal fibrosis or scar are less important than the global diffuse fibrosis and the increased distance for impulse propagation seen in LV dilation. In two studies, 23, 24 QRS was wider in more advanced NYHA class but multivariable analysis was not performed. In our study, NYHA class was associated with QRS prolongation in univariable but not multivariable analysis, suggesting NYHA class is a marker for other factors affecting QRS width, such as severity of HF, but not in itself a risk factor for QRS prolongation. Table 2) .
Male gender is associated with wider QRS in the general population, 6 ,25 and here we show that male gender increased the odds of QRS prolongation in HF by 65%. This was independent of all covariates, suggesting that larger cardiac size is important. QRS width ≥120 ms is the cut-off for CRT (in NYHA III -IV), regardless of gender, 1 but recent data suggest that women may respond better to CRT, 26, 27 suggesting that in women, the severity of electromechanical dyssynchrony may be greater for a given QRS width. Heart failure is associated with progressive remodelling and small studies suggest that QRS progressively prolongs in dilated cardiomyopathy 28 and after myocardial infarction. 29 In our study, duration of HF ≥6 months compared with new onset (,6 months) was associated with a 37% increase in the odds of having QRS ≥120 ms. This was independent of other markers of progression, such as EF, suggesting that progressive remodelling in the conduction system itself contributes.
Prognostic impact of QRS prolongation
In the general population, QRS prolongation may predict future need of pacemaker, 4 cardiovascular mortality, 30 and possibly but not conclusively 6, 31 all-cause mortality. In HFrEF, most 8 -10 but not all 11, 12 studies suggest that QRS prolongation/LBBB is associated with increased cardiovascular or all-cause mortality. These studies are of varying size and with variable adjustment for confounders. Here we show that in HF overall, QRS ≥120 ms was associated with 32% increased hazard for death in univariable analysis and 11% increased hazard after adjustment for 40 covariates. The hazard was progressive and linear, with a 4% increase per 10 ms in univariable analysis and 3% in multivariable analysis. The difference in magnitude in uni-and multivariable analyses suggests that QRS prolongation is a marker of other risk factors and severity of HF, but the presence of an independent hazard suggest that it is also a causative risk factor.
Prognostic impact of QRS prolongation in milder heart failure NYHA class was not independently associated with QRS prolongation, but once present, QRS prolongation could be associated with different risk depending on NYHA class. Although the interaction between QRS width and NYHA class was not significant, there was a signal towards greater risk with better NYHA class. Thus, in mild HF, the relative importance of QRS prolongation and thus the potential benefit of CRT may be greater, adding credence to recent studies of CRT in mild HF. 32, 33 In these studies, entry criteria were QRS ≥120 and 130 ms, respectively, but the recent European Society of Cardiology guidelines recommend a QRS ≥150 ms for CRT in milder HF. 34 If QRS prolongation can be confirmed to be more harmful in milder HF, perhaps this indication should be expanded.
Left bundle branch block
Most studies report data on QRS prolongation 4, 10, 11 or BBB/ LBBB, 5, 6, 8, 9 but not both, and the relative prevalence and prognostic importance of LBBB are poorly understood, although LBBB appears more responsive to CRT than non-specific intraventricular conduction delay and particularly, RBBB. 35 In our study, QRS prolongation was harmful, independent of LBBB, and when analysed separately, both LBBB and non-specific intraventricular conduction delay were similarly harmful.
Prognostic impact of QRS prolongation in heart failure with preserved ejection fraction
The role of QRS prolongation in HFpEF is poorly studied. Nonspecific QRS prolongation has not been studied, but in small studies, LBBB was present in 8 -40%, with conflicting impact on outcome. 9, 14 We show that QRS width predicted mortality independent of EF and that there was no interaction between EF and QRS width, although there was a signal towards lesser risk with preserved EF. Overall, QRS prolongation was harmful whether analysed as a categorical variable (most useful for clinical decisionmaking and with regard to CRT indication) or as a continuous variable (containing more detailed physiological information). In prespecified subgroup analysis, EF 40 -49 and ≥50% did not reach statistical significance for QRS ≥120 vs. ,120 ms, but was significant and of equal magnitude for QRS width as a continuous variable. Taken together, these data suggest that QRS prolongation is an independent risk factor for all-cause mortality also in HFpEF, and set the stage for potential trials of CRT in HFpEF. Interestingly, patients included in PROSPECT but with a core laboratory EF .35% may have derived similar benefit from CRT as those with lower EF. 36 
Limitations
Our study has limitations. QRS width was entered at local medical centres and was not subject to adjudication. Indeed, there are no firm criteria for establishing QRS width. 37 The registry contains data on QRS width and LBBB but does not separate non-specific intraventricular conduction delay vs. RBBB. N-terminal pro-brain natriuretic peptide was not in widespread use until the later years of the study and was missing in and imputed for 74.8% of patients. To avoid potential confounding due to excessive imputation, rather than exclude NT-proBNP from our analyses altogether, we performed a separate sensitivity analysis without NT-proBNP, which altered the HR only from 1.11 to 1.14, both P , 0.001. We do not have data on subsequent hospitalization or device implantation. QRS prolongation was an independent predictor of mortality after adjustment for a large number of covariates known to predict prognosis, suggesting but not proving it is not merely a risk marker but also a risk factor for mortality. However, we cannot rule out that unknown and/or unmeasured confounders may explain some of this risk.
Conclusion
We show that QRS prolongation occurs in HF and is independently associated most strongly not only with dilated cardiomyopathy and lower EF but also with age, male gender, and duration of HF. Notably, it is not independently associated with severity of disease and thus may occur equally often in milder disease. QRS prolongation and LBBB are also independent risk factors for all-cause mortality, also in preserved EF and milder HF. Our findings should be validated in independent prospective studies.
The independent association of QRS prolongation and LBBB with mortality suggests that they are risk factors amenable to intervention, and provides a rationale for prospective trials of CRT in HFpEF and potentially for expanded indications for CRT in milder HF.
